BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 24283755)

  • 1. Acute myeloid leukemia with DNMT3A mutations.
    Li Y; Zhu B
    Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A in Leukemia.
    Brunetti L; Gundry MC; Goodell MA
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
    Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
    Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.
    Yang L; Liu Y; Zhu L; Xiao M
    Leuk Lymphoma; 2015; 56(10):2914-22. PubMed ID: 25721756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
    Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia-associated DNMT3A p.Arg882His mutation in a patient with Tatton-Brown-Rahman overgrowth syndrome as a constitutional mutation.
    Kosaki R; Terashima H; Kubota M; Kosaki K
    Am J Med Genet A; 2017 Jan; 173(1):250-253. PubMed ID: 27991732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNMT3A mutations in acute myeloid leukemia.
    Ley TJ; Ding L; Walter MJ; McLellan MD; Lamprecht T; Larson DE; Kandoth C; Payton JE; Baty J; Welch J; Harris CC; Lichti CF; Townsend RR; Fulton RS; Dooling DJ; Koboldt DC; Schmidt H; Zhang Q; Osborne JR; Lin L; O'Laughlin M; McMichael JF; Delehaunty KD; McGrath SD; Fulton LA; Magrini VJ; Vickery TL; Hundal J; Cook LL; Conyers JJ; Swift GW; Reed JP; Alldredge PA; Wylie T; Walker J; Kalicki J; Watson MA; Heath S; Shannon WD; Varghese N; Nagarajan R; Westervelt P; Tomasson MH; Link DC; Graubert TA; DiPersio JF; Mardis ER; Wilson RK
    N Engl J Med; 2010 Dec; 363(25):2424-33. PubMed ID: 21067377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
    Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
    Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutational and expressional analysis of DNMT3A in acute myeloid leukemia cytogenetic subgroups.
    Zare-Abdollahi D; Safari S; Movafagh A; Riazi-Isfahani S; Ghadyani M; Hashemi-Gorji F; Feyzollah HG; Nasrollahi MF; Omrani MD
    Hematology; 2015 Aug; 20(7):397-404. PubMed ID: 25592687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
    Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
    J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
    Marcucci G; Metzeler KH; Schwind S; Becker H; Maharry K; Mrózek K; Radmacher MD; Kohlschmidt J; Nicolet D; Whitman SP; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Mar; 30(7):742-50. PubMed ID: 22291079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.
    Chaudry SF; Chevassut TJ
    Biomed Res Int; 2017; 2017():5473197. PubMed ID: 28286768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
    Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
    Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3A mutations in Chinese childhood acute myeloid leukemia.
    Li W; Cui L; Gao C; Liu S; Zhao X; Zhang R; Zheng H; Wu M; Li Z
    Medicine (Baltimore); 2017 Aug; 96(31):e7620. PubMed ID: 28767575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.